Literature DB >> 22532274

Bortezomib-induced severe autonomic neuropathy.

A Stratogianni1, M Tosch, H Schlemmer, J Weis, I Katona, S Isenmann, C A Haensch.   

Abstract

Peripheral neuropathy is a known side effect of bortezomib therapy. Acute autonomic neuropathy may also follow treatment with this cytotoxic agent used for treatment of multiple myeloma. Here, we report clinical characteristics and patterns of autonomic involvement in a 75-year-old patient who presented with recurring syncopes.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22532274     DOI： 10.1007/s10286-012-0164-8

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN： 0959-9851            Impact factor:   4.435


  8 in total

Review 1.  Chemotherapy-induced peripheral neuropathy.

Authors:  Stefan Quasthoff; Hans Peter Hartung
Journal:  J Neurol       Date:  2002-01       Impact factor: 4.849

2.  Cardiac denervation in postural tachycardia syndrome.

Authors:  Carl-Albrecht Haensch; Hartmut Lerch; Anna Jigalin; Hans Schlemmer; Stefan Isenmann
Journal:  Clin Auton Res       Date:  2007-09-26       Impact factor: 4.435

3.  Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study.

Authors:  Giuseppe Lauria; Mayienne Bakkers; Christoph Schmitz; Raffaella Lombardi; Paola Penza; Grazia Devigili; A Gordon Smith; Sung-Tsieh Hsieh; Svein I Mellgren; Thirugnanam Umapathi; Dan Ziegler; Catharina G Faber; Ingemar S J Merkies
Journal:  J Peripher Nerv Syst       Date:  2010-09       Impact factor: 3.494

4.  Gastroparesis in myotonic dystrophy 1.

Authors:  Carl-Albrecht Haensch; J Wehe; A Jigalin; S Isenmann
Journal:  Clin Auton Res       Date:  2010-12-02       Impact factor: 4.435

5.  Small-fiber neuropathy in patients with ALS.

Authors:  J Weis; I Katona; G Müller-Newen; C Sommer; G Necula; C Hendrich; A C Ludolph; A-D Sperfeld
Journal:  Neurology       Date:  2011-06-07       Impact factor: 9.910

6.  Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study.

Authors:  Maria Pia Giannoccaro; Vincenzo Donadio; Carolina Gomis Pèrez; Walter Borsini; Vitantonio Di Stasi; Rocco Liguori
Journal:  Neurol Sci       Date:  2011-02-03       Impact factor: 3.307

Review 7.  Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.

Authors:  Andreas A Argyriou; Gregoris Iconomou; Haralabos P Kalofonos
Journal:  Blood       Date:  2008-06-23       Impact factor: 22.113

8.  Non-length dependent small fibre neuropathy/ganglionopathy.

Authors:  K C Gorson; D N Herrmann; R Thiagarajan; T H Brannagan; R L Chin; L J Kinsella; A H Ropper
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-10-02       Impact factor: 10.154
  8 in total
  7 in total

Review 1.  Cardiovascular Autonomic Dysfunction in Patients with Cancer.

Authors:  Ben G T Coumbe; John D Groarke
Journal:  Curr Cardiol Rep       Date:  2018-07-03       Impact factor: 2.931

2.  Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma.

Authors:  Matthew Ho; Maria Moscvin; Soon Khai Low; Benjamin Evans; Sara Close; Robert Schlossman; Jacob Laubach; Claudia Paba Prada; Brett Glotzbecker; Paul G Richardson; Giada Bianchi
Journal:  Leuk Lymphoma       Date:  2022-06-14

3.  Bortezomib in first-line therapy is associated with falls in older adults with multiple myeloma.

Authors:  Kelly L Schoenbeck; Mark A Fiala; Tanya M Wildes
Journal:  J Geriatr Oncol       Date:  2021-03-07       Impact factor: 3.929

4.  Systemic Amyloidosis and Cardiac Autonomic Neuropathy Associated with Waldenstrom's Macroglobulinemia.

Authors:  Aasems Jacob; Rishi Raj; Warren Walkow
Journal:  Case Rep Hematol       Date:  2017-06-13

5.  Attenuation of STAT3 Signaling Cascade by Daidzin Can Enhance the Apoptotic Potential of Bortezomib against Multiple Myeloma.

Authors:  Min Hee Yang; Sang Hoon Jung; Arunachalam Chinnathambi; Tahani Awad Alahmadi; Sulaiman Ali Alharbi; Gautam Sethi; Kwang Seok Ahn
Journal:  Biomolecules       Date:  2019-12-23

6.  A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.

Authors:  Takashi Watanabe; Kensei Tobinai; Morio Matsumoto; Kenshi Suzuki; Kazutaka Sunami; Tadao Ishida; Kiyoshi Ando; Takaaki Chou; Shuji Ozaki; Masafumi Taniwaki; Naokuni Uike; Hirohiko Shibayama; Kiyohiko Hatake; Koji Izutsu; Takayuki Ishikawa; Yoshihisa Shumiya; Tomohisa Kashihara; Shinsuke Iida
Journal:  Br J Haematol       Date:  2016-01-05       Impact factor: 6.998

Review 7.  An Overview of Bortezomib-Induced Neurotoxicity.

Authors:  Cristina Meregalli
Journal:  Toxics       Date:  2015-07-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.